News & Events about Nkarta Inc.
Nkarta, Inc. (NASDAQ:NKTX Get Rating) has been given a consensus rating of Moderate Buy by the ten analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on ...
Globe Newswire
3 months ago
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Production of NK Cell Therapy ...
Ticker Report
4 months ago
Nkarta, Inc. (NASDAQ:NKTX Get Rating) CEO Paul J. Hastings sold 6,126 shares of the firms stock in a transaction that occurred on Wednesday, September 21st. The stock was sold at an average price of $13.01, for a total transaction of $79,699.26. Following the completion of the ...
Market News Video
4 months ago
In trading on Monday, shares of Nkarta Inc (NKTX) crossed below their 200 day moving average of 12.95, changing hands as low as 12.60 per share. Nkarta Inc shares are currently trading off about 5% on the day...
Nkarta, Inc. (NASDAQ:NKTX Get Rating) shares gapped up before the market opened on Monday after Raymond James raised their price target on the stock from $17.00 to $32.00. The stock had previously closed at $7.77, but opened at $10.30. Raymond James currently has an outperform rating on the stock. ...